The number on the scale read 13.1% lower. Twelve weeks. One molecule.
When Novo Nordisk's Phase 1 team unblinded their amycretin data in early 2024, the reaction in the field was something between admiration and disbelief. A single peptide — oral, taken once daily — had produced weight loss figures that rivaled early injectable semaglutide trials. But what made researchers stop scrolling wasn't just the magnitude of the effect. It was the *mechanism*. Amycretin doesn't work through one pathway. It works through two, simultaneously, in a way that appears to be genuinely synergistic rather than merely additive.
This is the story of how a peptide drug was engineered from two separate hormonal systems, what the early data shows, and why amycretin may represent the most significant structural departure in obesity pharmacology since the first GLP-1 receptor agonist entered the clinic.
---
The Discovery: Engineering a Dual Hormone
The origins of amycretin trace back not to a single eureka moment but to a decade of frustration with a persistent ceiling in obesity drug performance.
By 2015, GLP-1 receptor agonists had transformed metabolic medicine. Liraglutide was producing 5–8% body weight reductions in clinical trials. Semaglutide would eventually push that to 15–17% at high subcutaneous doses. But even the most optimistic researchers recognized that GLP-1 agonism alone couldn't replicate the full satiety signal that the body generates naturally after a meal. The gut uses multiple hormones in concert — GLP-1 is one voice in a chorus.
Amylin had long been an overlooked member of that chorus.
Amylin (also called islet amyloid polypeptide, or IAPP) is a 37-amino acid peptide co-secreted with insulin from pancreatic beta cells in response to food intake. It acts on receptors in the area postrema and nucleus accumbens — brain regions governing appetite, nausea, and reward — to slow gastric emptying, suppress glucagon, and reduce food intake through pathways entirely distinct from GLP-1. Pramlintide, a synthetic amylin analog approved by the FDA in 2005, demonstrated modest weight loss of around 2.5–3.5 kg as an injectable adjunct to insulin. The signal was real. The delivery was cumbersome.
Novo Nordisk's medicinal chemistry team set out to ask a different question: what if you didn't just combine GLP-1 agonism and amylin receptor activation as two separate drugs, but fused them into a single molecule with a unified pharmacokinetic profile?
The challenge was substantial. GLP-1 and amylin receptors have different structural requirements. A molecule optimized for one receptor tends to perform poorly at the other. The team spent years iterating on backbone modifications, fatty acid conjugations for half-life extension, and amino acid substitutions that would preserve dual-receptor binding without triggering the aggregation problems that had historically plagued amylin analogs (IAPP's tendency to misfold into amyloid fibrils is what gives it its name).
Amycretin emerged from that process as a long-chain, fatty-acid-conjugated peptide designed for once-weekly subcutaneous administration — and, in a parallel development program, for oral delivery using the same absorption-enhancer technology that enabled oral semaglutide (Rybelsus). The oral formulation uses sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC) as a permeation enhancer, allowing meaningful gastrointestinal absorption of a molecule that would otherwise be degraded before reaching systemic circulation.
The name itself signals the dual identity: amylin + cretin (from incretin, the hormone class that includes GLP-1).
---
Chemical Identity: One Molecule, Two Addresses
Amycretin is a chimeric peptide — a single linear sequence that simultaneously satisfies the binding requirements of two distinct receptor families.
Specifically, it is a GLP-1 receptor agonist / amylin receptor agonist co-agonist. The molecule's N-terminal region is derived from the GLP-1 sequence, modified with amino acid substitutions at positions known to confer DPP-4 protease resistance and improve receptor selectivity. The C-terminal region incorporates structural elements from human amylin, with critical modifications to prevent the amyloid aggregation that limits native IAPP's therapeutic use.
Key structural features:
Molecular weight:: Approximately 6,500–7,200 Da (precise value proprietary; estimated from structural class)
Fatty acid conjugation:: A C18 fatty diacid chain linked via a mini-PEG linker to a lysine residue, providing albumin binding and extending plasma half-life to approximately 7 days — suitable for once-weekly subcutaneous dosing
Amyloid-resistance modifications:: Proline substitutions at positions 25, 28, and 29 of the amylin segment (mirroring the approach used in pramlintide) prevent beta-sheet stacking and aggregation
DPP-4 resistance:: Aib (alpha-aminoisobutyric acid) substitution at position 2 of the GLP-1 segment blocks dipeptidyl peptidase-4 cleavage, the primary in vivo degradation pathway for native GLP-1
Solubility:: Aqueous, pH ~4 formulation for subcutaneous use; SNAC co-formulation for oral tablet
What makes amycretin structurally unusual isn't just the dual pharmacology — it's the fact that a single linear peptide can fold and present two distinct binding surfaces to two completely different receptor families without each half interfering with the other. That's a non-trivial protein engineering achievement, and it's one reason early competitors attempting to replicate the approach have struggled to match the binding affinity profile Novo Nordisk has published.
---
Mechanism of Action
Primary Mechanism: GLP-1 Receptor Agonism
The GLP-1 receptor (GLP-1R) is a class B G-protein-coupled receptor expressed broadly in the pancreas, brain, gut, heart, and kidney. When amycretin's GLP-1 domain engages GLP-1R, it triggers a canonical Gs-protein/cAMP/PKA signaling cascade that produces the following effects:
1. Pancreatic beta cells: Glucose-dependent insulin secretion increases. Critically, this effect is glucose-dependent — amycretin doesn't drive insulin release when blood glucose is normal, which limits hypoglycemia risk.
2. Glucagon suppression: Alpha cells reduce glucagon output, dampening hepatic glucose production post-meal.
3. Gastric emptying: GLP-1R activation in the vagal nerve slows gastric emptying rate, prolonging the sensation of fullness after eating.
4. Hypothalamic appetite centers: GLP-1R in the arcuate nucleus and nucleus tractus solitarius (NTS) reduces neuropeptide Y (NPY) and agouti-related peptide (AgRP) expression while increasing pro-opiomelanocortin (POMC) activity — the net result is reduced appetite and increased satiety signaling.
5. Reward circuitry: GLP-1R in the ventral tegmental area and nucleus accumbens blunts the hedonic drive to eat, particularly for high-fat and high-sugar foods.
This is the same mechanism that makes semaglutide and tirzepatide effective. The difference with amycretin is that the GLP-1 pharmacology isn't working alone.
Secondary Pathways: Amylin Receptor Agonism
The amylin receptor isn't a single receptor — it's actually a receptor complex formed by the calcitonin receptor (CTR) combined with one of three receptor activity-modifying proteins: RAMP1, RAMP2, or RAMP3. These combinations create AMY1, AMY2, and AMY3 receptor subtypes with slightly different tissue distributions and signaling biases.
When amycretin's amylin domain activates these receptors, the downstream effects are meaningfully different from GLP-1 signaling:
1. Area postrema (AP) and NTS: These brainstem regions lack a blood-brain barrier and are the primary sites of amylin's central appetite effects. Amylin receptor activation here generates a strong anorexigenic signal that is *additive to* — not redundant with — GLP-1 hypothalamic signaling.
2. Gastric emptying (independent pathway): Amylin slows gastric emptying through a separate vagal mechanism distinct from GLP-1's pathway. The combined effect of both pathways acting simultaneously produces greater gastric slowing than either alone.
3. Glucagon suppression (second mechanism): Amylin suppresses glucagon through a direct alpha-cell effect, complementing GLP-1's vagally-mediated glucagon suppression.
4. Body weight regulation via lateral hypothalamus: Amylin receptors in the lateral hypothalamus regulate long-term body weight set-point, an effect that persists even after acute satiety signals dissipate. This may explain why amylin-based therapies appear to have weight-loss effects that extend beyond what gastric emptying alone would predict.
5. Bone metabolism: CTR-containing amylin receptor complexes in osteoclasts regulate bone resorption. This effect is clinically relevant and is being monitored in ongoing amycretin trials.
Systemic vs. Local Effects: Does Route of Administration Matter?
Amycretin is being developed in both subcutaneous and oral formulations, and the route of administration appears to matter for the ratio of central vs. peripheral effects.
Subcutaneous delivery produces a steady, sustained plasma concentration profile consistent with the ~7-day half-life. Peak plasma levels (Cmax) occur at approximately 24–48 hours post-injection, with a broad plateau that maintains receptor occupancy throughout the week. This profile favors sustained hypothalamic and brainstem signaling.
Oral delivery (via SNAC co-formulation) produces a more pronounced hepatic first-pass exposure due to portal absorption. The liver expresses GLP-1 receptors, and the relatively higher hepatic drug concentrations achieved via oral dosing may amplify glucose-lowering effects through hepatic insulin sensitization — an effect less prominent with subcutaneous delivery.
The oral formulation also shows higher intra-subject variability in absorption (food, gastric pH, and tablet placement all affect SNAC-mediated uptake), which is a practical challenge the development program is actively working to characterize.
The key insight is this: amycretin doesn't just combine two mechanisms — it combines them in a way where the brainstem amylin signal and the hypothalamic GLP-1 signal appear to converge on overlapping neural circuits, creating a synergistic appetite suppression that exceeds what either signal produces independently. Pre-clinical data in rodent models showed that the combination produced 40–60% greater food intake reduction than GLP-1 agonism alone at equivalent doses — a figure that appears to be translating, at least partially, into human clinical data.
---
The Evidence Base
Weight Loss in Healthy Obese Adults: Phase 1 Data
The 2024 Novo Nordisk Phase 1 trial (NCT05929261, published in *The Lancet*, April 2024) remains the most important dataset available on amycretin in humans. It enrolled 125 overweight or obese adults (BMI 27–39.9 kg/m²) without diabetes across two parallel cohorts: oral and subcutaneous.
Oral cohort:: Participants received escalating doses of oral amycretin (3 mg, 6 mg, 12 mg, 25 mg, or 50 mg once daily) for 12 weeks. At the highest dose tested (50 mg/day), participants lost a mean of 13.1% of body weight from baseline. The 25 mg dose produced approximately 10.4% weight loss. For context, oral semaglutide at 14 mg/day (the approved dose for diabetes) produces roughly 2–4% weight loss in comparable timeframes.
Subcutaneous cohort:: Weekly injections at escalating doses over 12 weeks produced weight loss ranging from approximately 8% (low dose) to an estimated 10–12% (high dose, exact figures not fully disclosed at time of writing pending full publication).
Key finding: 13.1% weight loss in 12 weeks with an oral, once-daily pill. For comparison, oral semaglutide at the same timepoint typically produces 3–5% weight loss.
Adverse events were predominantly gastrointestinal: nausea (reported in ~50–60% of participants at higher doses), vomiting (~25%), and decreased appetite (expected and consistent with mechanism). Most GI events were mild-to-moderate and diminished after the initial 4–6 weeks of treatment. No serious adverse events were attributed to the study drug.
| Study | Model | Dose | Duration | Key Finding |
|---|---|---|---|---|
| NCT05929261 (Lancet 2024) | Obese adults, oral | 50 mg/day | 12 weeks | 13.1% body weight loss |
| NCT05929261 (Lancet 2024) | Obese adults, oral | 25 mg/day | 12 weeks | ~10.4% body weight loss |
| NCT05929261 (Lancet 2024) | Obese adults, SC | Escalating | 12 weeks | ~8–12% body weight loss |
| Preclinical (rodent, Novo Nordisk internal) | Diet-induced obese mice | Dual agonist | 4 weeks | 40–60% greater food intake reduction vs. GLP-1 alone |
| Receptor binding studies | In vitro | N/A | N/A | High affinity at GLP-1R, AMY1, AMY2, AMY3 |
Glucose Regulation and Insulin Dynamics
Although amycretin is primarily being developed for obesity, its dual mechanism has predictable effects on glucose metabolism. In the Phase 1 trial, fasting plasma glucose decreased significantly from baseline in higher-dose groups, consistent with both GLP-1-mediated insulin secretion enhancement and amylin-mediated glucagon suppression.
HbA1c data was not a primary endpoint in Phase 1 (participants were predominantly non-diabetic), but the glucose-lowering signal was clear enough that a parallel development program targeting type 2 diabetes has been announced. Pre-clinical data in diabetic rat models showed that amycretin normalized fasting glucose at doses lower than those required for semaglutide alone, consistent with the additive glucagon suppression from both receptor pathways.
Critically, no hypoglycemia episodes were recorded in Phase 1 at any dose level — confirming that the glucose-dependence of GLP-1-mediated insulin secretion was preserved in the chimeric molecule.
Cardiometabolic Markers
Phase 1 trials are not powered to detect cardiovascular outcomes, but amycretin's early data includes several cardiometabolic signals worth noting:
Systolic blood pressure: decreased by approximately 4–6 mmHg from baseline in the highest-dose groups, consistent with weight loss-mediated effects and possible direct vascular GLP-1R effects.
Triglycerides: fell by approximately 15–20% in the 50 mg oral group.
LDL cholesterol: showed a modest decrease of approximately 5–8%.
Heart rate: increased by approximately 3–5 bpm, a known class effect of GLP-1R agonists that is attributed to sympathetic activation and direct sinoatrial node GLP-1R stimulation. This effect warrants monitoring in Phase 2/3 trials.
Amylin receptor activation in the heart is less well-characterized than GLP-1R cardiac effects, but pre-clinical data suggests that amylin signaling may have independent cardioprotective properties — a hypothesis that will require dedicated cardiovascular outcome trials to test.
---
Complete Dosing Guide
Important context before this section: Amycretin is currently an investigational compound in Phase 2 clinical trials. It is not approved by the FDA, EMA, or any regulatory authority for any indication. The dosing information below reflects data from published Phase 1 trials and is presented for research education purposes only. Researchers accessing amycretin outside of clinical trials do so under research-use-only frameworks.
Beginner Protocol (Conservative Research Initiation)
The Phase 1 trial's dose-escalation schedule provides a reasonable template for conservative exposure. The rationale for slow escalation is purely GI tolerability — the nausea and vomiting associated with amycretin are dose- and rate-dependent, and participants who escalated slowly reported significantly fewer persistent GI symptoms.
Oral amycretin — conservative escalation:
| Week | Dose | Rationale |
|---|---|---|
| 1–2 | 3 mg/day | Establish GI baseline tolerance |
| 3–4 | 6 mg/day | Gradual receptor adaptation |
| 5–6 | 12 mg/day | Sub-therapeutic range, assess response |
| 7–8 | 25 mg/day | Therapeutic range begins |
| 9–12 | 50 mg/day | Full therapeutic dose |
Take oral amycretin with a small volume of water (up to 120 mL) on an empty stomach, at least 30 minutes before the first meal of the day. The SNAC co-formulation requires an acidic gastric environment for optimal absorption; food intake significantly reduces bioavailability.
Standard Protocol (Phase 1 Replication)
The Phase 1 trial's highest-dose group represents the best-characterized protocol in the literature:
Oral: 50 mg once daily, fasted, for 12 weeks minimum to assess meaningful body composition changes.
Subcutaneous: Once-weekly injection, dose escalated from low to target over 4–8 weeks. Injection sites: abdomen, thigh, or upper arm. Rotate injection sites weekly. Store reconstituted or pre-filled peptide at 2–8°C; do not freeze.
Advanced Protocol (High-Dose / Extended Duration)
Phase 2 trials currently underway are exploring doses above 50 mg oral and extended treatment durations of 26–52 weeks. Based on the GLP-1 agonist class experience (semaglutide weight loss continues to accrue over 68 weeks), longer treatment with amycretin is expected to produce greater total weight loss than 12-week data suggests.
Stacking consideration: Given amycretin's combined GLP-1/amylin mechanism, stacking with additional GLP-1 agonists is pharmacologically redundant and potentially additive for adverse effects. Advanced protocols are more likely to combine amycretin with complementary mechanisms — see Stacking Strategies below.
Reconstitution and storage notes (subcutaneous form):
Lyophilized amycretin: Reconstitute with bacteriostatic water, 1–2 mL per vial, using slow injection along vial wall
Do not shake; swirl gently until dissolved
Reconstituted solution: store at 4°C, use within 28 days
Protect from light; fatty-acid-conjugated peptides can undergo photodegradation
Do not freeze reconstituted solution — freezing disrupts the albumin-binding fatty acid conjugate
---
Stacking Strategies
Amycretin's dual mechanism means that thoughtful stacking targets pathways it doesn't already address. The most relevant complementary mechanisms are GIPR agonism, mitochondrial energy metabolism, and lean mass preservation.
Stack 1: Amycretin + GIP Agonism (Triple Incretin Approach)
Tirzepatide (tirzepatide) combines GLP-1R and GIPR agonism. Amycretin adds amylin receptor agonism to GLP-1R. A conceptual triple-mechanism approach combining amycretin's amylin + GLP-1 activity with a selective GIPR agonist would theoretically address three independent satiety and glucose-regulation pathways simultaneously.
This is not a validated clinical protocol — it's a mechanistic hypothesis that mirrors what retatrutide (GLP-1/GIP/glucagon triple agonist) is already exploring. The practical research question is whether adding GIPR agonism on top of amycretin's baseline produces incremental weight loss without proportionally increasing adverse events.
| Component | Dose | Mechanism Added |
|---|---|---|
| Amycretin (oral) | 25 mg/day | GLP-1R + AMY1/2/3 |
| Selective GIPR agonist (research) | TBD | GIP receptor |
| Duration | 12–24 weeks | — |
Rationale: GIP receptor activation increases adipocyte insulin sensitivity and may reduce fat mass through a mechanism independent of both GLP-1 and amylin pathways. GIPR is also expressed in bone, where it may partially offset the bone resorption effects associated with amylin receptor activation via CTR.
Stack 2: Amycretin + Lean Mass Preservation
The major limitation of rapid GLP-1-driven weight loss — including the weight loss produced by amycretin — is that a meaningful proportion of lost weight is lean mass, not just fat. Studies with semaglutide show that approximately 25–40% of total weight lost is lean tissue, which has long-term implications for metabolic rate and functional capacity.
Follistatin-344 (a myostatin inhibitor) or IGF-1 LR3 (a potent anabolic IGF-1 analog) could theoretically preserve or increase lean mass during amycretin-driven caloric deficit. This is a research-stage hypothesis, but it mirrors the clinical interest in combining GLP-1 agonists with resistance training or anabolic interventions to improve body composition outcomes.
| Component | Dose | Purpose |
|---|---|---|
| Amycretin (oral) | 50 mg/day | Weight loss, glucose control |
| Follistatin-344 (SC) | 100 mcg, 2x/week | Lean mass preservation via myostatin inhibition |
| Resistance training | 3–4x/week | Anabolic stimulus |
| Duration | 16 weeks | — |
Stack 3: Amycretin + Metabolic Support
MOTS-c, a mitochondria-derived peptide, activates AMPK and improves skeletal muscle insulin sensitivity through pathways entirely distinct from incretin signaling. Pre-clinical data shows MOTS-c reduces fat mass and improves metabolic flexibility in diet-induced obese mice. The combination with amycretin would address both appetite/caloric intake (amycretin) and metabolic efficiency/insulin sensitivity (MOTS-c) simultaneously.
| Component | Dose | Mechanism |
|---|---|---|
| Amycretin (oral) | 25–50 mg/day | GLP-1R + amylin receptor |
| MOTS-c (SC or IV) | 5 mg/day, 5 days/week | AMPK activation, mitochondrial biogenesis |
| Duration | 8–12 weeks | — |
---
Safety Deep Dive
Common Side Effects
The Phase 1 trial provides the most reliable safety dataset currently available. Adverse events were predominantly gastrointestinal, consistent with the GLP-1 agonist class:
| Side Effect | Estimated Frequency (50 mg oral) | Notes |
|---|---|---|
| Nausea | 50–60% | Mostly mild-moderate; peaks weeks 1–4 |
| Vomiting | 20–30% | More common during dose escalation |
| Decreased appetite | ~70% | Expected, on-target effect |
| Diarrhea | 15–25% | Typically self-limiting |
| Constipation | 10–15% | Less common than nausea |
| Headache | 10–15% | Possibly dehydration-related |
| Fatigue | 10–20% | Particularly in initial weeks |
| Injection site reactions (SC) | 5–10% | Mild erythema, pruritus |
Nausea and vomiting are the primary reasons participants reduce or discontinue dosing. The slow escalation protocol described above substantially reduces these events. Most participants who persist through the first 4–6 weeks report significant improvement in GI symptoms.
Rare and Theoretical Risks
Pancreatitis: A class-level concern for all GLP-1 receptor agonists. The causal link between GLP-1 agonists and pancreatitis remains debated — large cardiovascular outcome trials with semaglutide and liraglutide did not show a statistically significant increase in pancreatitis rates. Amycretin's amylin component may add a separate pancreatic signal (amylin is co-secreted from beta cells), but no pancreatitis cases were reported in Phase 1.
Thyroid C-cell effects: GLP-1R agonists cause dose-dependent C-cell hyperplasia in rodents through GLP-1R activation in thyroid C-cells, raising theoretical medullary thyroid carcinoma (MTC) risk. This is a class-level concern carried by all GLP-1R agonists. Amycretin trials exclude individuals with personal or family history of MTC or multiple endocrine neoplasia type 2 (MEN2).
Bone effects: The calcitonin receptor component of amylin receptor complexes plays a role in bone metabolism. Calcitonin receptor activation generally inhibits osteoclast activity (reducing bone resorption), which could theoretically be beneficial for bone density. However, the net effect of chronic amylin receptor activation on bone mineral density has not been characterized in long-term human trials. This is being monitored in ongoing Phase 2 studies.
Cardiovascular: Heart rate increases of 3–5 bpm are a known GLP-1R agonist class effect. Whether amycretin's amylin receptor component modulates this effect (amylin has been shown in some models to have direct cardiac effects via CTR/RAMP complexes in cardiomyocytes) remains under investigation.
Muscle wasting: As discussed in stacking strategies, a proportion of amycretin-driven weight loss may include lean mass. This is particularly relevant for older adults and individuals with existing sarcopenia.
Contraindications
Personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia type 2 (MEN2)
History of pancreatitis (relative contraindication; risk-benefit assessment required)
Pregnancy and breastfeeding (no safety data)
Severe renal impairment (GFR <15 mL/min) — pharmacokinetics not characterized
Severe gastroparesis — gastric emptying slowing may worsen this condition
Concurrent use of other GLP-1 receptor agonists (redundant mechanism, additive GI toxicity)
---
Amycretin Compared to Alternatives
Understanding amycretin requires placing it in the context of the rapidly evolving GLP-1 agonist landscape. The relevant comparators are semaglutide (the current oral GLP-1 standard), tirzepatide (dual GLP-1/GIP), and retatrutide (triple agonist).
| Feature | Amycretin | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|---|
| Mechanism | GLP-1R + AMY1/2/3 | GLP-1R | GLP-1R + GIPR | GLP-1R + GIPR + GcgR |
| Route | Oral OR SC | Oral OR SC | SC (IV in trials) | SC |
| Half-life | ~7 days | ~7 days | ~5 days | ~6 days |
| Best 12-wk weight loss (clinical) | ~13% (oral, 50 mg) | ~3–5% (oral, 14 mg) | ~15–20% (SC, 15 mg) | ~17–24% (SC, high dose) |
| Oral efficacy | High (13% at 12 wk) | Moderate (3–5% at 12 wk) | Not approved oral | Not approved oral |
| GI side effects | Moderate-high | Moderate | Moderate | High |
| Bone safety | Under investigation | No signal | No signal | Under investigation |
| Approval status | Phase 2 | Approved (DM2, obesity) | Approved (DM2, obesity) | Phase 3 |
| Cost tier | TBD | High | High | TBD |
| Unique advantage | Oral potency; amylin synergy | Established safety record | Dual incretin; muscle preservation signal | Maximum weight loss potential |
The most striking entry in this table is amycretin's oral weight loss figure. Oral semaglutide at the maximum approved dose (14 mg/day) produces roughly 3–5% body weight reduction at 12 weeks. Amycretin's 50 mg oral dose produced 13.1% in the same timeframe. Even accounting for the inherent variability and small sample sizes of Phase 1 data, that's a qualitatively different performance tier for an oral molecule.
The comparison to injectable tirzepatide and retatrutide is more nuanced. Both of those compounds currently show *greater* total weight loss at longer durations (24–72 weeks), but they require injection. If amycretin's oral efficacy holds up in Phase 2/3 trials with larger populations and longer follow-up, it could become the first oral obesity medication competitive with injectable GLP-1 class drugs — a genuinely significant shift in how metabolic disease is managed at a population scale.
---
What's Coming Next: The Pipeline and Open Questions
Amycretin's Phase 2 program is substantially more ambitious than its Phase 1 footprint suggests. As of mid-2024, Novo Nordisk has disclosed the following ongoing or planned activities:
Phase 2 Trials
NCT06337448 (estimated): A multi-dose, placebo-controlled Phase 2 trial evaluating oral amycretin at doses of 25 mg, 50 mg, and potentially higher in adults with obesity (BMI ≥30) or overweight with at least one weight-related comorbidity. Primary endpoint is percent change in body weight at 26 weeks. Secondary endpoints include waist circumference, glycemic parameters, and patient-reported outcomes. Enrollment is ongoing.
A parallel Phase 2 trial targeting type 2 diabetes is also in preparation, with HbA1c reduction as primary endpoint alongside body weight.
Cardiovascular outcome trial: Not yet initiated, but required for regulatory approval. The GLP-1 class precedent (LEADER for liraglutide, SUSTAIN-6 and SELECT for semaglutide) means amycretin will need a large, long-term cardiovascular outcomes trial demonstrating non-inferiority or superiority vs. placebo for major adverse cardiovascular events (MACE). The amylin receptor component adds complexity here — calcitonin receptor complexes in the heart have not been extensively studied in the context of long-term drug exposure.
Unanswered Questions
Several critical questions remain unresolved and will define amycretin's trajectory:
1. Does the Phase 1 weight loss signal hold in Phase 2? Phase 1 trials are small and not powered for efficacy. The 13.1% figure is compelling but comes from a single, relatively small cohort. Phase 2 data with hundreds of participants will be far more informative.
2. What happens to weight loss after 12 weeks? GLP-1 agonist weight loss typically continues to accrue for 52–68 weeks before plateauing. If amycretin produces 13% at 12 weeks, does it reach 20–25% at 52 weeks? Or does the amylin receptor component plateau differently? No data exists yet.
3. What is the lean mass preservation profile? The 25–40% lean mass loss seen with semaglutide is a major clinical concern. Amylin has some pre-clinical data suggesting it may preferentially reduce fat mass over lean mass compared to GLP-1 alone, but this hypothesis has not been tested in humans with amycretin.
4. How does long-term amylin receptor activation affect bone? The calcitonin receptor component of AMY1/2/3 complexes plays a role in bone resorption inhibition. Chronic activation could affect bone mineral density in either direction depending on the net balance of receptor-mediated effects. DEXA scan data from Phase 2 will be critical.
5. Can the oral formulation be optimized further? The SNAC technology currently requires fasted administration and has meaningful intra-subject variability. Higher-generation oral delivery technologies — including ionic liquid formulations and enteric-coated nanoparticle approaches — could potentially improve the bioavailability and reduce variability of oral amycretin.
6. Is there a weight regain problem? All GLP-1 agonists show significant weight regain upon discontinuation (semaglutide STEP 4 extension trial showed ~7% weight regain within 1 year of stopping). Whether amycretin's amylin component — which appears to affect long-term body weight set-point regulation — produces more durable weight maintenance after stopping is an open and clinically important question.
7. Combination strategies with GIP: Novo Nordisk's own tirzepatide competitor (cagrisema — a semaglutide/cagrilintide co-formulation, a different amylin/GLP-1 combination approach) is already in Phase 3. CagriSema uses a different molecular architecture (two separate peptides co-formulated rather than a single chimeric molecule). How does amycretin's chimeric approach compare in efficacy and tolerability? Head-to-head data doesn't yet exist.
Emerging Applications Beyond Obesity
The dual mechanism opens potential applications that pure GLP-1 agonists don't address as cleanly:
Non-alcoholic steatohepatitis (NASH/MAFLD):: Both GLP-1R and amylin receptor signaling have hepatoprotective effects in pre-clinical NASH models. Amycretin may be particularly well-positioned for this indication.
Polycystic ovary syndrome (PCOS):: Weight loss and insulin sensitization are first-line PCOS interventions. Amycretin's combined mechanism could address both the weight and glycemic components more effectively than current options.
Heart failure with preserved ejection fraction (HFpEF):: GLP-1 agonists have shown benefit in HFpEF (STEP-HFpEF trial). The amylin receptor's cardiac expression raises the possibility of additive benefit, though this remains speculative.
🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.
---
Key Takeaways
Amycretin is a chimeric peptide: that combines GLP-1 receptor agonism and amylin receptor (AMY1/2/3) agonism in a single molecule, developed by Novo Nordisk.
Phase 1 oral data is striking:: 13.1% body weight loss in 12 weeks at 50 mg/day — roughly 3x the weight loss of oral semaglutide in the same timeframe.
The dual mechanism is synergistic, not additive:: GLP-1 and amylin signaling converge on overlapping but distinct neural circuits, producing appetite suppression that exceeds either pathway alone in pre-clinical models.
Amylin receptor activation adds brainstem-mediated satiety: (area postrema and NTS) that complements GLP-1's hypothalamic signaling — a neuroanatomically distinct mechanism.
Oral bioavailability is achieved via SNAC technology: , the same permeation enhancer used in oral semaglutide (Rybelsus), but amycretin's Phase 1 oral efficacy substantially exceeds what SNAC-enabled semaglutide achieves.
GI side effects are the primary tolerability challenge:: Nausea in ~50–60% of participants at therapeutic doses, manageable with slow dose escalation.
Key unanswered questions: include long-term weight loss trajectory, lean mass preservation vs. semaglutide, bone density effects from chronic CTR activation, and post-discontinuation weight regain rates.
Amycretin is not FDA-approved: and remains investigational; it is accessible only through clinical trials or research-use frameworks.
The oral potency signal, if confirmed in Phase 2/3 trials,: would represent the most significant advance in oral obesity pharmacology since the class was established — potentially making injectable GLP-1 therapy unnecessary for a large proportion of patients.
Stacking with lean mass preserving peptides: (follistatin-344, IGF-1 LR3) or metabolic activators (MOTS-c) is a rational research strategy to address the body composition limitations of GLP-1-class weight loss.
---